Pharming Group N.V.’s (PHAR) supplemental New Drug Application seeking approval for Joenja as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS) is under priority review by the FDA, with a decision due on January 31, 2026.Activated phosphoinositide 3-kinase delta syndrome (APDS) is a rare primary immunodeficiency caused by variants in either one of two identified genes known as PIK3CD or PIK3R1, which are vital to the development and function of immune cells in the body. It is characterized by a variety of symptoms, including severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy.Joenja has been marketed in the U.S. for the treatment of APDS in adult and pediatric patients 12 years of age and older since 2023. The drug generated revenue of $15.1 million in the third quarter of 2025, an increase of 35% over the third quarter of 2024, reflecting strong growth.PHAR closed Monday’s (Dec.29, 2025) trading at $16.93, down 3.26%.